On the other hand, several plant-derived bioactive compounds may directly prevent NAFLD and hepatic steatosis by decreasing de novo lipogenesis through direct downregulating of the sterol regulatory element-binding protein 1c (SREBP-1c), increasing FAs oxidation through up-regulating the PPAR receptor and improving insulin sensitivity, and decreasing intestinal lipid absorption [85,86,87,88,89]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.